Pharmacodynamic analysis of tumour perfusion assessed by $^{15}$O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies

Andrew M Scott1*, Paul L Mitchell1, Graeme O’Keefe1, Timothy Sauder1, Rodney J Hicks2, Aurora Poon1, Charles Baum3, Nicoletta Brega4, Timothy J McCarthy5 and Guy C Toner2

Abstract

Background: We evaluated pharmacodynamic changes in tumour perfusion using positron emission tomography (PET) imaging with $^{15}$O-water to assess biological response to sunitinib, a multitargeted tyrosine kinase inhibitor.

Methods: Patients with advanced malignancies received sunitinib 50 mg/day orally, once daily for 4 weeks on treatment, followed by 2 weeks off treatment, in repeated 6-week cycles. Quantitative measurement of tumour perfusion was assessed using $^{15}$O-water-PET at baseline and after 2 weeks of treatment. At least one reference tumour lesion was included in the fields of view and assessed at both time points. Patients also underwent $^{18}$F-fluorodeoxyglucose (FDG)-PET imaging at baseline and after 2 and 4 weeks of treatment. Radiological response of the reference tumour lesion and overall radiological response were assessed at week 12. Serum pharmacokinetic and biomarker analyses were also performed.

Results: Data were available for seven patients. Compared with baseline, all patients experienced a decrease in reference tumour blood flow ranging from 20 % to 85 % and also a reduction in the FDG standard uptake value ranging from 29 % to 67 %. Six patients experienced a partial metabolic response based on FDG-PET criteria. Four patients had stable disease defined by radiological response (Response Evaluation Criteria in Solid Tumors) lasting between 4 and 12 cycles. An association between perfusion change and clinical benefit, and biomarker levels including vascular endothelial growth factor was observed.

Conclusion: Administering sunitinib to patients with advanced malignancies is associated with early biological responses, including decreased blood flow in secondary tumour deposits. 

Keywords: sunitinib, tumour perfusion, FDG-PET.

Background
Once solid tumours have reached an advanced or metastatic stage, treatment is largely palliative rather than curative, with the aim of prolonging survival, relieving pain and other symptoms, and maintaining or improving quality of life [1-3]. Pharmacotherapy at such advanced stages is generally targeted at slowing, halting, or - if possible - reversing tumour progression, and at reducing the chance of further metastasis.

Targeted biological therapies with antiangiogenic properties may be particularly beneficial in the palliative care setting by preventing the neovascularisation required for tumour progression beyond a certain size [4]. The early and more subtle biological effects of new antiangiogenic agents may not be detected by conventional measures of tumour response, which are based on changes in tumour size. Positron emission tomography (PET) imaging assesses functional aspects of tumour status and may detect biological responses (e.g.
decreased metabolic rate and blood flow) before changes in tumour size are apparent with conventional imaging techniques [5,6].

Sunitinib (Sutent®; Pfizer Inc., New York, NY, USA) is an orally active, multitargeted tyrosine kinase inhibitor with both antitumour and antiangiogenic effects. Its targets include vascular endothelial growth factor receptors 1, 2, and 3 (VEGFRs-1, -2, and -3), platelet-derived growth factor receptors α and β, stem-cell factor receptor, FMS-like tyrosine kinase 3, and glial cell line-derived neurotrophic factor receptor [7-12]. Sunitinib is approved in many countries for the treatment of gastrointestinal stromal tumours after disease progression on or intolerance to imatinib mesylate therapy [13], for the treatment of advanced renal cell carcinoma [14], and for the treatment of advanced pancreatic neuroendocrine tumours [15].

In a pilot study of 55 adults with advanced malignancies treated with sunitinib, biological activity and antitumour effects were seen in a broad range of tumour types [16]. Seven patients continued therapy for more than 12 months, and two patients remained on therapy more than 3 years after enrolment. Two types of antitumour activity were seen: tumour shrinkage and central tumour necrosis. Serial PET imaging detected ≥20 % reductions in the standard uptake value (SUV) of \(^{18}\)F-fluoro-2-deoxy-D-glucose (FDG) as early as the second week of treatment. Both PET response and clinical benefit correlated with trough plasma levels of sunitinib and its principal metabolite (SU12662). The present paper reports on a subset of seven patients from this study who, in addition to standard study procedures, also underwent pharmacodynamic assessment with quantitative \(^{15}\)O-water-PET imaging to assess the effects of sunitinib treatment on tumour perfusion.

Methods

Patients and treatment

The use of FDG-PET and other PET-based imaging techniques to assess biological response to sunitinib was investigated in a 12-week, open-label, prospective pilot study involving four groups. The present study describes the group of patients who underwent \(^{15}\)O-water- and FDG-PET imaging. All patients were ≥18 years old, with radiological evidence of metastatic or advanced malignancy for which there was no available therapy with curative potential. Other key eligibility criteria included Karnofsky performance status > 60 %, life expectancy > 12 weeks without rapidly progressive disease, and adequate liver function (aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN); AST or ALT ≤ 5.0 × ULN or bilirubin ≤ 1.5 × ULN if liver function abnormalities were due to underlying malignancy), renal function (serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance > 40 mL/min by the Cockcroft-Gault formula), and bone marrow function (absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L, platelets ≥ 75 × 10^9/L, and haemoglobin > 10 g/L; ANC ≥ 1.0 × 10^9/L, platelets ≥ 50 × 10^9/L, or haemoglobin > 10 g/L for patients with haematological malignancies and bone marrow involvement). At screening, all patients had to have at least one tumour mass detectable by FDG-PET imaging that was suitable for serial quantitative assessment and had not been included in a prior radiotherapy field. Female patients were postmenopausal, surgically sterile, or using effective contraception. Key exclusion criteria included the use of any other anticancer agent or investigational agent within 4 weeks prior to the start of sunitinib treatment, prior specific anti-vascular endothelial growth factor (VEGF) treatment, and any condition requiring treatment that was likely to affect the reliability of the serial PET assessments. Patients were also excluded if they had a medical or psychiatric condition that would limit full compliance with the study. Concomitant treatments necessary for the patients’ well-being were given at the discretion of the investigator. The study was carried out in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and was approved by an institutional review board. All patients provided written informed consent.

Patients received oral sunitinib 50 mg once daily for 4 weeks on treatment, followed by 2 weeks off treatment (schedule 4/2) in repeated 6-week cycles. The primary study period was the first two cycles (12 weeks) of treatment. Patients benefiting from the treatment were permitted to receive additional cycles of sunitinib for up to 1 year. The study drug was discontinued in patients exhibiting grade 4 haematological toxicity, grade 3 thrombocytopenia with haemorrhage of grade 3/4, or grade 3/4 non-haematological toxicity, and only restarted when the ANC recovered to ≥ 1.5 × 10^9/L and platelet count to 75 × 10^9/L.

Study assessments

Tumour perfusion

Tumour perfusion was assessed using a radioactive tracer (\(^{15}\)O-water) and PET imaging. This technique allowed quantification of the arterial concentration of \(^{15}\)O-water and calculation of the perfusion rate. Quantification of blood flow within the tumour (expressed in millilitre per gram per minute) was performed.

\(^{15}\)O-water-PET imaging was performed at baseline and after 2 weeks of treatment using an ECAT 951/31R scanner (CTI PET Systems, Knoxville, TN, USA), employing 16 rings of bismuth germanate oxide block detectors with an axial extent of 108 mm and a spatial resolution of 5.4 mm at the scanner’s centre of field of...
view. At least one viable reference tumour lesion identified by FDG-PET scanning was included in the field of view and was assessed at both time points. Emission scans were acquired dynamically in three-dimensional (3D) mode during bolus intravenous injections of 370 MBq of $^{15}$O-water into the antecubital vein. The dynamic acquisition consisted of 11 frames acquired over 3 min with $4 \times 5$-s, $2 \times 10$-s, and $4 \times 30$-s frames. A transmission image (10-min acquisition) was also obtained. Dynamic dataset images were reconstructed with both 3D-filtered back-projection, using a 3D re-projection algorithm (3D-FORE/FBP), and 3D attenuation-weighted ordered-subsets expectation maximisation (AW-OSEM3D) [17,18]. As a result of the superior image quality of the AW-OSEM3D reconstruction, this was used for the subsequent analysis.

**Glucose uptake**

All patients had an FDG-PET scan at screening, up to 14 days prior to commencing sunitinib treatment. Further FDG-PET scans were performed at baseline and after 2 and 4 weeks of treatment, with SUV measurement of the glucose metabolism of both reference and overall tumour lesions. Whole body FDG-PET scanning was performed using a Philips Allegro dedicated PET scanner (Philips Medical Systems, Cleveland, Ohio, USA) under standardised conditions, following an overnight fast, and with imaging commencing exactly 60 min after FDG administration. All studies were performed with measured attenuation correction and were reconstructed using RAMLA 3D [19] and reconstructed in units of SUV. Blood glucose and lean body mass were recorded. Overall response (OR) was assessed in patients completing at least 4 weeks of treatment with all assessments performed. OR was defined as a $\geq 20\%$ reduction in FDG uptake as assessed by SUV corrected for lean body mass in all lesions present at baseline in the absence of any new lesions. Progressive disease (PD) was defined as a $\geq 15\%$ increase in FDG uptake in any lesion or emergence of any new lesions. A mixed response was defined as multiple lesions with an OR or PD, plus other lesions with stable disease.

**Image analysis of tumour perfusion**

The volume of interest (VOI) for the reference tumour for each patient was defined using the FDG-PET data by thresholding to approximately 75% of the maximum SUV in tumour and also by comparing to tumour size on computed tomography scan. The VOIs were defined for the baseline and 2-week post-treatment $^{15}$O-water studies using the associated baseline and 2-week post treatment FDG scan-determined VOIs. The entire VOI was used to determine the activity for $^{15}$O-water. By using the attenuation image for the FDG and $^{15}$O-water studies, the emission images from both studies were coregistered so that the reference tumour VOIs could be applied to the water study (Figure 1). A summed dynamic image from the $^{15}$O-water study was then used to define the descending aorta. The resultant tumour and aortic VOIs were used to determine the integrated activity for their respective regions, which then defined the response and input functions, respectively.

**Spectral analysis**

A one-tissue compartment model was used to calculate the tumour blood flow and comprised vascular and tissue compartments (Figure 2a). The operational equation defining tissue blood flow is given in Figure 2b, where $M(t)$ denotes the detected activity within a VOI and is made up of a vascular component given by $V(t)$ and an extra-vascular or tissue component $M(t)$, where $V_0$ denotes the vascular volume term, and $C_s(t)$, the arterial input term. Such a system is governed by a so-called one-tissue-compartment model dictated by the equation given in Figure 2c, where $K_1$ denotes the blood perfusion from vascular to tissue compartment, and $K_2$, the washout rate, as illustrated in Figure 2. The analytic solution to this differential equation is expressed in Figure 2d. Non-linear analytical techniques are adopted to solve for the rate constants $K_1$ and $K_2$.

For the purposes of this analysis, tumour blood perfusion was derived from this equation by using the tumour VOI to input data into the tissue compartment of this model. Normally, the vascular compartment is neglected in this model as it generally makes a small contribution (approximately 5%) to the net activity, thus reducing the analysis to a single-compartment model. However, for tumour regions, the high vascular density requires this term to be explicitly modelled [20]. Thus, both tissue perfusion and blood volume were determined. Spectral techniques were adopted in the analysis of tumour blood flow data due to the robustness of the linear approach and the input/response function delays. The equation in Figure 2e illustrates the linearisation process whereby a spectrum of exponentials convolved with the input function are predetermined so as to allow the linear solution for the blood-perfusion weighting terms given by $a_i$. By adopting such a spectrum of exponentials, the problem is linearised and, so, is less prone to noise effects in the measured data. The vascular term is incorporated implicitly by ranging the spectrum of exponentials from $p_i = 0$ to a predetermined maximum flow rate. Upon solving this system using standard linear techniques, the blood perfusion + vascular volume of the tumour is determined by summing the spectrum of $a_i$ components.
Spectral analysis model and operational equations. Spectral analysis model used to calculate tumour blood flow comprising vascular and tissue compartments (a), and the operational equation defining tissue blood flow (b) and (c) where \( M(t) \) denotes the detected activity within a volume of interest and is made up of a vascular component given by \( V_0C_a(t) \) and an extra-vascular or tissue component \( M_e(t) \), where \( V_0 \) denotes the vascular volume term, and \( C_a(t) \), the arterial input term. Such a system is governed by a so-called one-tissue-compartment model dictated by the equation given in (c). The analytic solution to this differential equation is expressed in (d). The equation in (e) illustrates the linearisation process whereby a spectrum of exponentials convolved with the input function are predetermined so as to allow the linear solution for the blood-perfusion weighting terms given by \( \alpha_i \).
Response assessment
Radiological response of the reference tumour lesion and overall radiological response were assessed at week 12 using Response Evaluation Criteria in Solid Tumors (RECIST) [21]. Clinical benefit was deemed to be present if the treating clinician judged that the patient was benefiting from treatment (RECIST-defined stable disease or response) and continued the therapy beyond the 12-week study period. Formal response evaluation and clinical benefit assessment were performed every 12 weeks for patients continuing to receive sunitinib after the second cycle of treatment.

Pharmacokinetic and biomarker analyses
Blood samples for analysis of pharmacokinetic parameters were collected on day 1 and every 14 days in cycle 1. Levels of sunitinib and its principal metabolite, SU12662, were determined using liquid chromatography and mass spectrometry techniques. Peripheral blood for biomarker analysis was collected before and 6 h after the first dose on day 1 and at every visit thereafter (i.e., every 14 days for the first 12 weeks). Samples were screened by enzyme-linked immunosorbent assays and 2D-gel electrophoresis for proteins whose levels may be altered in association with sunitinib activity or exposure: for example, VEGF and soluble VEGFR-2 (sVEGFR-2).

Statistical analysis
Data were summarised using descriptive statistics. Analysis of change in tumour perfusion or FDG-SUV was performed using the Student’s t test, comparing patients with clinical benefit to those without clinical benefit of treatment (one-sided t test, assumed unequal variance). Analysis of day 15 trough levels of sunitinib plus SU12662 was performed using a z-test for patients with clinical benefit and patients without clinical benefit and a reference of 50 ng/mL. Linear relationships between change in tumour perfusion or change in FDG-SUV and biomarker levels were determined using Pearson’s product moment correlation with 95% confidence intervals.

Results
Data are reported for seven patients who underwent all study investigations and completed at least two treatment cycles (Table 1). Dosing was delayed for patients 2 and 3 before starting cycle 2 of therapy, while the cycle 2 dose of patient 7 was reduced by 25%. Figure 3 illustrates the result of the spectral fitting procedure for patient 4 for pre- and post-treatment, with the associated estimation of tumour blood reported in the value of \( K_1 \). Partial volume effects were not considered as the tumour VOIs were of similar size for both pre- and post-treatment.

Table 1 details the site of the primary and reference tumours as well as the biological and radiological response of the reference tumour and overall tumour response to sunitinib therapy. All patients exhibited a decrease in reference tumour blood flow, ranging from 20% to 85%, and a reduction in FDG-SUV from baseline in the reference tumour, ranging from 29% to 67%. Six of the seven patients experienced a partial metabolic response at week 4 based on FDG-PET criteria. Four patients had stable disease lasting between four cycles (24 weeks) and 12 cycles (72 weeks) confirmed by RECIST at restaging.

Further analyses were undertaken in order to investigate potential correlations between percent reduction in tumour perfusion and clinical benefit, duration of therapy, percent reduction in FDG-SUV, plasma levels of sunitinib and SU12662, and changes in plasma levels of VEGF and sVEGFR-2 (Table 2, Figures 4 and 5). There was a possible association between the degree of change

| Patient | Primary tumour type | Reference tumour site | Change in perfusion at week 2 (%) | Change in FDG-SUV in reference tumour at week 2 (%) | Overall FDG-PET response at week 4 | Radiological response in reference lesion at week 12 | Overall radiological response at week 12 | Duration of treatment (number of 6-week cycles) | Clinical benefit |
|---------|---------------------|-----------------------|----------------------------------|----------------------------------------------|---------------------------------|-----------------------------------------------|---------------------------------|-----------------|----------------|
| 1       | Renal               | Right hepatic lobe    | −85                              | −39                                         | Yes                             | SD                                            | SD                              | 4               | Yes            |
| 2       | Colon               | Right hepatic lesion  | −77                              | −37                                         | Yes                             | SD                                            | SD                              | 6               | Yes            |
| 3       | Colon               | Right hepatic lobe    | −59                              | −33                                         | Yes                             | PD                                            | PD                              | 2               | No             |
| 4       | Colon               | Right hepatic lobe    | −34                              | −44                                         | Yes                             | PD                                            | PD                              | 2               | No             |
| 5       | NSCLC               | Left lung lesion      | −69                              | −67                                         | Yes                             | SD                                            | SD                              | 12              | Yes            |
| 6       | Colon               | Right hepatic lesion  | −38                              | −32                                         | Yes                             | SD                                            | SD                              | 7               | Yes            |
| 7       | Oesophageal         | Right hepatic dome    | −20                              | −29                                         | No                              | PD                                            | PD                              | 2               | No             |

Biological (week 2) and radiological (week 12) responses among patients with advanced malignancies treated with sunitinib 50 mg/day on schedule 4/2. Clinical benefit was deemed to be present if the treating clinician judged that the patient was benefiting from treatment and continued therapy beyond the 12-week study period. D15:D1, day 15/day 1 ratio; FDG-PET, \(^{18}\)F-fluorodeoxyglucose positron emission tomography; FDG-SUV, \(^{18}\)F-fluorodeoxyglucose standard uptake value; NSCLC, non-small cell lung cancer; PD, progressive disease; SD, stable disease.
in tumour perfusion measured after 2 weeks of therapy and subsequent clinical benefit (t test, \( p = 0.05 \); Figure 4a) as well as with duration of therapy (Figure 4b) and with change in biomarker levels, particularly VEGF (Figures 5b,c). A further non-significant trend was observed between VEGF biomarker levels and FDG-SUV (percent) change (sVEGFR2: \( r = 0.76, p > 0.05 \) and VEGF: \( r = 0.75, p > 0.05 \)). In this study, there was no evidence of correlation between the degree of change in tumour perfusion with the degree of FDG-SUV change (\( r = -0.09, p > 0.05 \); Figure 4c) or with trough levels of sunitinib plus SU12662 (Figure 5a). However, when comparing trough levels of sunitinib plus SU12662 with a clinical reference of 50 ng/mL, there was a significant change in levels in responsive patients (\( p < 0.001 \)) compared with those in patients who were not responsive to the therapy (\( p = 0.38 \)).

**Discussion**
The results of this study conclusively show that sunitinib treatment of adult patients with a variety of metastatic malignancies is associated with early biological responses, including decreased blood flow in secondary tumour deposits. The reduction in tumour blood flow was associated with a corresponding fall in FDG-SUV, consistent with a decrease in tumour metabolic rate. This is the first study to provide quantitative evidence of the pharmacodynamic effects of sunitinib on tumour blood flow by PET imaging. There was also a possible association between the degree of change in tumour perfusion measured after 2 weeks of therapy and subsequent clinical benefit, duration of therapy, and change in levels of the biomarker VEGF. Blockade of VEGFR signalling by sunitinib may lead to reduced VEGF uptake by VEGFR and, hence, increased circulating VEGF, which was seen in this study.

**Table 2** Change in tumour perfusion, FDG-SUV, clinical benefit, and pharmacokinetic and pharmacodynamic parameters following sunitinib treatment

| Patient | Baseline perfusion (mL/min/g) | Change in perfusion (%) | Baseline FDG-SUV | Change in FDG-SUV at week 2 (%) | Change in FDG-SUV at week 4 (%) | Clinical benefit | Day 15 trough levels of sunitinib plus SU12662 (ng/mL) | VEGF plasma levels D15:D1 | sVEGFR-2 plasma levels D15:D1 |
|---------|-------------------------------|-------------------------|-----------------|-------------------------------|-------------------------------|----------------|---------------------------------|----------------------|-------------------|
| 1       | 0.81                          | -85                     | 4.6             | -39                           | -48                           | Yes            | 76.4                            | 5.29                 | 0.66               |
| 2       | 1.18                          | -77                     | 6.5             | -37                           | -59                           | Yes            | 134.9                           | 4.85                 | 0.44               |
| 3       | 1.52                          | -59                     | 4.2             | -33                           | -29                           | No             | 90.8                            | 8.67                 | 0.34               |
| 4       | 1.28                          | -34                     | 9.8             | -44                           | -13                           | No             | 27.6                            | 2.56                 | 0.75               |
| 5       | 0.74                          | -69                     | 12.3            | -67                           | -66                           | Yes            | 107.1                           | 4.17                 | 0.49               |
| 6       | 1.39                          | -38                     | 6.0             | -32                           | -18                           | Yes            | 88.8                            | NA                   | NA                 |
| 7       | 1.23                          | -20                     | 4.1             | -29                           | -41                           | No             | 105.0                           | NA                   | NA                 |

*Clinical benefit was deemed to be present if the treating clinician judged that the patient was benefiting from treatment and continued therapy beyond the 12-week study period. **Target trough level for therapeutic effect was considered > 50 ng/mL D15:D1, day 15:day 1 ratio; FDG-SUV, 18F-fluorodeoxyglucose standard uptake value; NA, not available; VEGF, vascular endothelial growth factor; sVEGFR-2, soluble vascular endothelial growth factor receptor 2.*
Not every patient who had a fall in tumour perfusion went on to have a conventional tumour response. Possible explanations for this lack of correlation include a mismatched assessment timing for tumour perfusion (at 2 weeks) and radiological response (at 12 weeks), allowing for tumour progression after an initial early response. Dosing was delayed in one patient, and the dose was reduced in another of the three patients with progressive disease at 12 weeks, which may have influenced the clinical tumour response despite an earlier decrease in tumour perfusion. Mixed responses, with the reference tumour showing a response but other tumour deposits showing progression, and stable or enlarging tumour masses despite central necrosis, could also account for the observed lack of correlation between tumour perfusion and conventional response. In this context, PET imaging may be informative regarding initial pharmacodynamic changes in response to sunitinib treatment, but may not be predictive of the final response.

The methodology used in this study for assessing tumour perfusion changes was based on established techniques and adapted to enable quantitative analysis of tumour perfusion with $^{15}$O-water-PET without requiring an arterial line. The use of $^{15}$O-water-PET for the quantitation of blood flow is well established; it is a reliable method to assess the pharmacodynamics of therapeutic agents with a mechanism of action involving angiogenesis inhibition [22]. The short half-life of $^{15}$O-water does restrict its use to PET centres with on-site cyclotrons. Additional limitations of this study that preclude definitive conclusions include the small sample size and heterogeneous nature of the cases. In addition, there may be a sampling error associated with the selection of target lesions when multiple lesions are present.

Blood flow in solid tumours is often increased relative to the surrounding tissue [23-25]. Moreover, tumour progression beyond a certain size requires active angiogenesis, making antiangiogenic therapy an attractive target for new drug development. Previous studies have indicated a relationship between clinical response, in terms of disease-free survival, and a combination of FDG and tumour perfusion measurements in patients receiving chemotherapy for advanced breast cancer [23]. The role of VEGF-PET as a biomarker of dynamic angiogenic changes has recently been investigated [26]. The effects of sunitinib treatment were assessed using the VEGF-PET tracer $^{89}$Zr-ranibizumab in mouse xenograft models of human cancer. VEGF-PET demonstrated dynamic changes during sunitinib treatment, with a strong decline in signal in the tumour centre and only minimal reduction in the tumour rim, with a pronounced rebound after sunitinib discontinuation. In

![Figure 4](image-url)
Figure 5 Correlation between reduction in tumour perfusion and trough levels of total drug, VEGF, and sVEGFR-2. Potential correlations between percent reduction in tumour perfusion and day 15 trough levels of total drug (sunitinib plus SU12662; \( p > 0.05 \)) (a), change in plasma VEGF levels \(( p = 0.05 \)) (b), and change in plasma sVEGFR-2 levels \(( p > 0.05 \)) (c). D15:D1, day 15:day 1 ratio.
addition, VEGF-PET results corresponded with tumour growth and immunohistochemical vascular and tumour markers.

Conclusions

The results presented here indicate that sunitinib therapy is associated with early biological responses and measurable pharmacodynamic changes in tumour blood flow and metabolism. These data provide important insights into the antitumour effects of sunitinib in this patient population.

Competing interests

PLM received funding from Pfizer for a laboratory-based research on the prevalence of EML4-ALK mutations in lung cancer patients. RJH received funding support from Pfizer for the Translational Lab and PET Centre via his institution (Peter MacCallum Cancer Centre, Melbourne, Australia). CB, NB, and TJM are Pfizer employees and hold Pfizer stock. GCT acted as a consultant for Pfizer, received honoraria for attending international and Australian advisory board meetings, and received travel sponsorship to attend international meetings, including meetings at which this study was reported; his institution (Peter MacCallum Cancer Centre, Melbourne, Australia) received funding support from Pfizer for the Translational Lab and PET Centre. The other authors have no competing interests to declare.

Authors’ contributions

AMS participated in the design of the molecular imaging components of the study and coordination of molecular imaging data analysis and acquisition. PLM participated in the design and coordination of the study, and analysis. GOK was involved in the design of the imaging studies and data analysis. TS performed the PET data collection and image analysis. RJH was involved in the conception and design of the molecular imaging components of the clinical trial of which this study represents a subgroup. AP assessed the site of the metabolically active malignancy on the patients’ baseline FDG-PET studies and then decided on the tumour site where the 18F-water studies would be acquired and aid in subsequent image analysis. CB was responsible for the clinical development of sunitinib and was therefore involved in the conception, design, and execution of the study, and data evaluation. NB was involved in conceiving of the study and participated in the study design and coordination. TJM reviewed the data and the manuscript. GCT was involved in the conception of the project, protocol writing, patient accrual, and data analysis. All authors were involved in the drafting of the manuscript and approved the final version for submission.

Acknowledgments

We would like to thank all of the participating patients and their families as well as the investigators, research nurses, study coordinators, and operations staff. This study was sponsored by Pfizer Inc. Editorial support was provided by Nicola Crofts at ACUMED. This study was sponsored by Pfizer Inc. Editorial support was provided by Nicola Crofts at ACUMED. This study was sponsored by Pfizer Inc. Editorial support was provided by Nicola Crofts at ACUMED.

References

1. Bidor M, Alexander C, Edelman MJ: Management of common symptoms of advanced lung cancer. Curr Treat Options Oncol 2005, 6(1):51-68.
2. Dixon MR, Starnes MJ: Strategies for palliative care in advanced colorectal cancer. Dis Surg 2004, 21:344-341.
3. Ruan DT, Warren RS: Palliative techniques for hepatic cancer. Surg Oncol Clin N Am 2004, 13:505-516.
4. Isobe T, Herbst RS, Onn A: Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 2005, 32(5):315-328.
5. Scott AM: Current status of positron emission tomography in oncology. Intern Med J 2001, 31:27-36.
6. Marzola P, Degrassi A, Calderan L, Fanace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pensi E, Terron A, Sbarbati A, Olsalati F: Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005, 11:5827-5832.
7. Abrams TJ, Lee LB, Murray LJ, Pyer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2:471-478.
8. Mendel DB, Lard AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chen E, Moss KG, Haznedar IO, Subkuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
9. O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Wong H, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597–3605.
10. Murray LJ, Abrams TJ, Long KR, Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Kest PP, Braszad JA, O’Farrell AM, Cherrington JM, Pyer NK: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003, 20:757–766.
11. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M: An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/PTC kinases. J Clin Endocrinol Metab 2006, 91:4070–4076.
12. Pfizer Limited: SUTENT™ Summary of Product Characteristics [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000687/WC50057737.pdf] Accessed January 19, 2012.
13. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Blackstein ME, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368: 1329–1338.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Durdarev S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115–124.
15. Raymond E, Dahan L, Raouf JL, Bang YJ, Borabith I, Lombard-Bomas C, Vallie J, Metakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cauteren E, Patyna S, Lu DR, Blankmeister C, Zhao R, Ruszniewski P, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:51–58.
16. Tozer K, Mitchell PL, de Boer R, Gibbons P, Hicks R, Scott AM, Brega N, Massimini G, Scialla P: PET imaging study of SU11248 in patients with advanced malignancies [abstract]. Proc Am Soc Clin Oncol 2003, 22:674.
17. Kinalh P, Rogers J: Analytic 3D image reconstruction using all detected events. IEEE Trans Nucl Sci 1980, 36:964-968.
18. Michel C, Sibomana M, Boi A, Bernard X, Lonneux M, Defrise M, Comtat C, Kinalh PE, Townsend DW: Preserving Poisson characteristics of PET data with weighted OSEM reconstruction. In IEEE Nuclear Science Symposium: November 8–14 1998. 2nd edition, Toronto, IEEE 1998:1323–1326.
19. Accorsi R, Adam LE, Werner ME, Karp JS: Implementation of a single scatter simulation algorithm for 3D PET: application to emission and transmission scanning. In IEEE Nuclear Science Symposium: November 10–16 2002. 2nd edition. Piscataway: IEEE; 2003:816–820.
20. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM: Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003, 21:2823–2830.

21. Therasse P, Arbitun SG, Eitenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216.

22. Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckely P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR, on behalf of the California Cancer Consortium: SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003, 9:4772–4781.

23. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB: Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002, 43:500–509.

24. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T: Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992, 52:1592–1597.

25. Yamaguchi A, Taniguchi H, Kunishima S, Koh T, Yamagishi H: Correlation between angiographically assessed vascularity and blood flow in hepatic metastases in patients with colorectal carcinoma. Cancer 2000, 89:1236–1244.

26. Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Wamders FJ, Brouwers AH, de Jong JR, Price PM, Hoöema H, Hespers GA, Eisinga PH, Hesselix NN, de Vries Gieterman JA: EGVEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2011, 71:143–153.

doi:10.1186/2191-219X-2-31
Cite this article as: Scott et al: Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. EJNMMI Research 2012 2:31.
Author/s: Scott, AM; Mitchell, PL; O'Keefe, G; Saunter, T; Hicks, RJ; Poon, A; Baum, C; Brega, N; McCarthy, TJ; Toner, GC

Title: Pharmacodynamic analysis of tumour perfusion assessed by O-15-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies

Date: 2012-01-01

Citation: Scott, A. M., Mitchell, P. L., O'Keefe, G., Saunder, T., Hicks, R. J., Poon, A., Baum, C., Brega, N., McCarthy, T. J. & Toner, G. C. (2012). Pharmacodynamic analysis of tumour perfusion assessed by O-15-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. EJNMMI RESEARCH, 2 (1), https://doi.org/10.1186/2191-219X-2-31.

Persistent Link: http://hdl.handle.net/11343/261536

File Description: Published version

License: CC BY